Larson Financial Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Larson Financial Group’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14	Closed	-$121	–	2780
2024 Q2	$121	Hold	14	–	–	﹤0.01%	2208
2024 Q1	$123	Hold	14	–	–	﹤0.01%	1684
2023 Q4	$104	Hold	14	–	–	﹤0.01%	1706
2023 Q3	$81	Buy	14 +1	+8%	+$7	﹤0.01%	1667
2023 Q2	$96	Hold	13	–	–	﹤0.01%	1526
2023 Q1	$98	Hold	13	–	–	﹤0.01%	1499
2022 Q4	$89	Hold	13	–	–	﹤0.01%	1462
2022 Q3	$0	Buy	+13	New	+$164	﹤0.01%	1423

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Larson Financial Group's TLIS Position: Q3 2024 in Review

Larson Financial Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 14 shares — an estimated $121 sold.

Larson Financial Group first reported a position in TLIS in Q3 2022 and held it in 8 quarters. The position peaked at $123 in Q1 2024. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Larson Financial Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Larson Financial Group sold 14 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $121.
Larson Financial Group first reported a position in Talis Biomedical Corporation Common Stock in Q3 2022 and held it in 8 quarters.
Larson Financial Group's Talis Biomedical Corporation Common Stock position peaked at $123 in Q1 2024.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Larson Financial Group's 13F filing for Q3 2024, filed 12 Nov 2024.